Do we foresee new emerging drugs to treat malignant hyperthermia?
Malignant hyperthermia (MH) is a life-threatening genetic sensitivity of skeletal muscles to volatile anesthetics and depolarizing neuromuscular blocking drugs occurring during or after anesthesia. Mortality of MH has been significantly reduced by using the skeletal muscle relaxant dantrolene. However, pharmacological disadvantages are known. By approval of a nanocrystalline dantrolene sodium suspension (DSS), a new product enters the market. DSS is a promising substance, but clinical data are lacking up to now. Especially with regard to newer knowledge on MH and its associated clinical presentations, there might be an increasing interest on DSS.
Witten/Herdecke University, Hospital Cologne-Merheim, Cologne Medical Centre, Department of Anaesthesiology , Ostmerheimer Strasse 200, Cologne , Germany.
Katja S
KS
Just
Mark U
MU
Gerbershagen
Joern
J
Grensemann
Frank
F
Wappler
D000769:Anesthesia, Inhalation / Q000009:adverse effects; D003620:Dantrolene / Q000008:administration & dosage / Q000627:therapeutic use*; D017277:Drug Approval; D006801:Humans; D008305:Malignant Hyperthermia / Q000188:drug therapy* / Q000235:genetics / Q000401:mortality; D053758:Nanoparticles; D009467:Neuromuscular Depolarizing Agents / Q000009:adverse effects
D009467:Neuromuscular Depolarizing Agents; D003620:Dantrolene
anesthesia; dantrolene; dantrolene sodium suspension; malignant hyperthermia; nanocrystalline suspension